Sun Pharmaceutical Industries announced its largest-ever acquisition on Monday, April 27, 2026, signing a definitive agreement to acquire the US-based healthcare company Organon & Co. in an all-cash deal with an enterprise valuation of $11.75 billion.
The transaction marks the biggest outbound deal ever by an Indian pharmaceutical company, positioning Sun Pharma to become a top-25 global pharmaceutical player.
1. Deal Financials and Structure
Sun Pharma will acquire all outstanding shares of Organon for $14.00 per share in cash.
- Enterprise Value: $11.75 Billion.
- Financing: The deal will be funded through approximately $2 billion to $2.5 billion in internal cash reserves, with the remaining $9.25 billion to $9.75 billion coming from committed bank financing.
- Timeline: The boards of both companies have approved the deal. It is expected to close in early 2027, pending regulatory clearances and approval from Organon stockholders.
- Leverage: Post-transaction, Sun Pharma expects a Net Debt/EBITDA ratio of 2.3x, with plans to use the combined entity’s strong cash flow (estimated at $2.5 billion free cash flow) for rapid deleveraging.
2. Strategic Rationale: A “Transformational” Move
The acquisition is designed to move Sun Pharma beyond traditional generics into high-margin “Innovative Medicines” and specialized therapeutic areas.
- Women’s Health Powerhouse: Organon is a global leader in women’s health (contraception, fertility). The merger will make Sun Pharma a top 3 global player in this segment.
- Biosimilars Entry: The deal serves as an “entry ticket” into the high-growth biosimilars market, instantly making Sun Pharma a top 10 global biosimilar player.
- Global Footprint: Organon operates in over 140 countries with six manufacturing facilities in the EU and emerging markets. The combined entity will have a presence in 150 countries.
- Revenue Scale: The merged company is expected to have a combined revenue of $12.4 billion, with “Innovative Medicines” accounting for 27% of the total revenue share.
3. Market and Analyst Reaction
The Indian markets responded with notable optimism despite the heavy debt involved in the transaction.
- Stock Surge: Sun Pharma’s share price jumped 6.8% to 7% on the day of the announcement, trading at approximately ₹1,731 on the NSE.
- Market Sentiment: Investors appear to favor the deal because Organon is a profitable, cash-generating business (reporting $6.2 billion revenue and $1.9 billion EBITDA in 2025) rather than a speculative asset.
- Analyst View: Analysts at Choice Institutional Equities called the move a “transformational scale-up,” though they noted that long-term success will depend on managing integration risks and the speed of debt repayment.
4. About Organon & Co.
Organon was formed in 2021 as a spin-off from Merck & Co. (known as MSD outside the US/Canada). It holds a portfolio of over 70 products across Women’s Health and General Medicines (Established Brands).
| Metric (CY2025) | Organon Financial Status |
| Revenue | $6.2 Billion |
| Adjusted EBITDA | $1.9 Billion |
| Debt | $8.6 Billion |
| Cash Balance | $574 Million |